Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2022 Feb 10

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Medica 2022 Feb 10

DOI: 10.23736/S0026-4806.22.08024-7

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

New drugs under development for COPD

Isabel UWAGBOE 1, Ian M. ADCOCK 1 , Federica LO BELLO 2, Gaetano CARAMORI 2, Sharon MUMBY 1

1 Airways Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2 Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università di Messina, Messina, Italy


PDF


The characteristic features of chronic obstructive pulmonary disease (COPD) include inflammation and remodelling of the lower airways and lung parenchyma together with activation of inflammatory and immune processes. Due to the increasing habit of cigarette smoking worldwide COPD prevalence is increasing globally. Current therapies are unable to prevent COPD progression in many patients or target many of its hallmark characteristics which may reflect the lack of adequate biomarkers to detect the heterogeneous clinical and molecular nature of COPD. In this chapter we review recent molecular data that may indicate novel pathways that underpin COPD subphenotypes and indicate potential improvements in the classes of drugs currently used to treat COPD. We also highlight the evidence for new drugs or approaches to treat COPD identified using molecular and other approaches including kinase inhibitors, cytokine- and chemokine-directed biologicals and small molecules, antioxidants and redox signalling pathway inhibitors, inhaled anti-infectious agents and senolytics. It is important to consider the phenotypes/molecular endotypes of COPD patients together with specific outcome measures to target new therapies to particular COPD subtypes. This will require greater understanding of COPD molecular pathologies and a focus on biomarkers of predicting disease subsets and responder/non-responder populations.


KEY WORDS: COPD; Exacerbation; Pathogenesis; New drugs; Therapy

inizio pagina